Efficacy and safety of certolizumab pegol after incomplete response to DMARDs in RA patients with low moderate disease activity: Results from CERTAIN, a phase IIIB study

Non ancora tradotto Non ancora tradotto
Categoria Primary study
GiornaleAnn Rheum Dis
Year 2011
Questo articolo non ha abstract
Epistemonikos ID: 05da4b654e2c13c2644d6caf037482a1890e72cc
First added on: Dec 16, 2023